Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Biogen Inc. (NASDAQ: BIIB).

Full DD Report for BIIB

You must become a subscriber to view this report.


Recent News from (NASDAQ: BIIB)

Your Daily Scoop: Recro Proceeds, MannKind Zooms, Aduro's Publication
News in focus: REPH, MNKD Recro Pharma plans to resubmit NDA Discussion : On September 4, Recro Pharma ( REPH ) reported positive outcome of its meeting with the FDA regarding its NDA for IV meloxicam that was rejected in last May. Based on the discussion with the FDA, the comp...
Source: SeekingAlpha
Date: September, 07 2018 16:31
Small Caps Are Rising, Biotechs Can't Be Far Behind
Market Pulse The S&P 500 has finally emerged from its 7-month consolidation as it weaves its way back to chalking all-time highs. While that is an event worth acknowledging, it may not be as breathless a milestone when one realizes that the small cap Russell 2000 index led the market and...
Source: SeekingAlpha
Date: September, 05 2018 13:31
Enrollment underway in late-stage study of Biogen's BIIB093 in severe type of ischemic stroke
The first patient has been enrolled in a Phase 3 clinical trial, CHARM , evaluating Biogen's (NASDAQ: BIIB ) intravenous (IV) glibenclamide (BIIB093) for the prevention and treatment of severe cerebral edema in large hemispheric infarction (LHI), a severe type of ischemic stroke with a po...
Source: SeekingAlpha
Date: September, 04 2018 08:16
Biogen Enrolls First Patient in Global Phase 3 Study of BIIB093 (IV Glibenclamide) for Large Hemispheric Infarction
CHARM study will evaluate IV glibenclamide for the prevention and treatment of severe cerebral edema in LHI, one of the most severe types of ischemic stroke with limited treatment options Prior studies demonstrated IV glibenclamide may potentially improve functional outcomes and reduce mo...
Source: GlobeNewswire
Date: September, 04 2018 07:30
Pfizer mid-stage flop with domagrozumab in DMD another setback for myostatin inhibitors - Endpoints News
Endpoints News' John Carroll reports that Pfizer's failure with domagrozumab in Duchenne muscular dystrophy (DMD) is another black eye for myostatin inhibitors for muscle wasting disorders. More news on: Novartis AG, Amgen Inc., Atara Biotherapeutics, Healthcare stocks news, Read mor...
Source: SeekingAlpha
Date: August, 30 2018 12:36
By The Numbers: Is Biogen A Buy?
Biogen ( BIIB ) is one of the top players in the biotech industry, and the company benefits from a strong position in treatments for neurological and neurodegenerative diseases, such as multiple sclerosis (NYSE: MS ) and neuroimmunology, Alzheimer’s disease and dementia, movement disord...
Source: SeekingAlpha
Date: August, 30 2018 10:00
By The Numbers: Growth Leaders With Strong Momentum
Investing in high-growth stocks can generate outstanding returns when done right. In essence, a stock is simply a share in the ownership of a business, and businesses with superior growth rates tend to generate higher returns for investors over the long term. However, implementing a solid gr...
Source: SeekingAlpha
Date: August, 28 2018 10:24
Biogen's Alzheimer's candidate aducanumab maintains risk-benefit profile in long-term extension study
Biogen (NASDAQ: BIIB ) and development partner Eisai ( OTCPK:ESALY ) announce results from an ongoing long-term Phase 1b extension study evaluating aducanumab for the treatment of mild cognitive impairment in patients with Alzheimer's disease (AD) and mild AD dementia. More news on: Biog...
Source: SeekingAlpha
Date: August, 28 2018 08:02
Biogen and Eisai Report Data from Long-Term Extension Phase 1b Study of Investigational Alzheimer's Disease Treatment Aducanumab
Data Includes Additional Analyses of Long-Term Extension Phase 1b Study With Titration Cohort at 36 Months and Fixed-Dose Cohorts at 48 Months CAMBRIDGE, Mass., Aug. 28, 2018 (GLOBE NEWSWIRE) -- Biogen (Nasdaq: BIIB) and Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Ei...
Source: Thomson Reuters ONE
Date: August, 28 2018 07:30
Money flow stays positive in biotechs, XBI up 6% since last week
Biotechs continue their modest rally. The SPDR S&P Biotech ETF ( XBI +1.9% ) is up albeit on below average. It has jumped  6%  since last week. More news on: SPDR Biotech ETF, Ionis Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the ...
Source: SeekingAlpha
Date: August, 27 2018 11:39

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-09-08340.00339.65341.69336.27997,638
2018-05-17280.26280.57281.62277.261,830,683
2018-05-11274.36282.39283.59274.361,908,861
2018-05-10272.65274.00276.26272.101,416,613
2018-05-09269.75274.03275.72269.071,377,304

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-1060,987140,53643.3960Short
2018-12-07114,057185,32061.5460Short
2018-12-06124,323258,13648.1618Short
2018-12-0488,620173,88450.9650Short
2018-12-0365,801175,91437.4052Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on BIIB.


About Biogen Inc. (NASDAQ: BIIB)

Logo for Biogen Inc. (NASDAQ: BIIB)

Not available

 

Contact Information

 

 

Current Management

  • Thomas J. Bucknum / Secretary

Current Share Structure

  • Market Cap: $59,575,983,191 - 05/14/2018
  • Issue and Outstanding: 211,007,945 - 04/20/2018

 


Recent Filings from (NASDAQ: BIIB)

Notice of exempt solicitation. Definitive material
Filing Type: PX14A6GFiling Source: edgar
Filing Date: May, 03 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 27 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: April, 27 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 24 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: April, 24 2018
Notice of exempt solicitation. Definitive material
Filing Type: PX14A6GFiling Source: edgar
Filing Date: March, 27 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 08 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: February, 01 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: January, 29 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: January, 25 2018

 

 


Daily Technical Chart for (NASDAQ: BIIB)

Daily Technical Chart for (NASDAQ: BIIB)


Stay tuned for daily updates and more on (NASDAQ: BIIB)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: BIIB)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in BIIB is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of BIIB and does not buy, sell, or trade any shares of BIIB. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/